Amarin Corp plc (ADR) (NASDAQ:AMRN)

CAPS Rating: 3 out of 5

The Company is engaged in the research, development and commercialization of novel drugs for the treatment of central nervous system disorders.

AMRN News and Commentary

Caps

How do you think AMRN will perform against the market?

Add Stock to CAPS Watchlist

All Players

304 Outperform
27 Underperform
 

All-Star Players

34 Outperform
8 Underperform
 

Wall Street

1 Outperform
1 Underperform
 

Top AMRN Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Rilac (96.69)
Submitted October 11, 2013

after perusing the brief documents for the adcom on the 16th, it seems as if the price movement for Amarin has been over exaggerated. i read nothing really abhorrent. nonetheless i took in a position before today's closing

chris293 (66.53)
Submitted May 07, 2013

FDA approval for fish oil? What else is going on here, are they selling the good parts of the company for what?

AMRN VS S&P 500 (SPY)

Fools bullish on AMRN are also bullish on:

Fools bearish on AMRN are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about AMRN.

Recs

0
Member Avatar RMITRA757 (96.64) Submitted: 7/5/2017 10:12:16 AM : Outperform Start Price: $3.05 AMRN Score: +5.70

bought for RLP on 7/5/2017 @ 4.36

Recs

0
Member Avatar MarkBiotech (47.48) Submitted: 4/5/2017 2:53:02 AM : Outperform Start Price: $3.15 AMRN Score: +0.15

At first glance Vascepa may seem like your ordinary omega 3 supplement, but in actuality, there is a distinct difference between Vascepa and ordinary omega 3 supplements:

-only contains EPA oppose to standard EPA&DHA
-Lowers LDL cholesterol due to absence of DHA
-Patented release formula
-Chromatography purification method
- 96% omega 3 content per 860mg

The potential for Vascepa is unlimited as awareness for the benefits of omega 3's continue to grow. The omega 3 global market will reach 19B by 2022.

If Vascepa taps into a small percentage of that market, we can see Amarin stock hit multi-bagger valuations. With reduce-it study, vascepa will ultimately expand its label and tap into this immense market. Going forward, second Reduce-it interim analysis is due late 3Q of 2017. Final data is due 2018. Multiple of studies have proved CV reduction including the ELIS study, which showed a 19-53% CV reduction. This undoubtedly proves Vascepa will come out top when reduce-it study reads out.

Going forward, dilution has been a major problem for Amarin shareholders, as it has seen over a 50% rise in outstanding shares over the past 5 years. This was to fund its expensive reduce it study and to develop Vascepa's market. However, the tides will change, and Amarin will reach profitability by late 2018-2019.Until profitability, I'm expecting no more than 80-120M in secondary dilutions which is relatively small in comparison to its combined past offerings.

Closing limit-PT10

Recs

0
Member Avatar adamicius (< 20) Submitted: 3/29/2017 4:43:24 AM : Outperform Start Price: $3.22 AMRN Score: -2.81

growing market share for Vascepa, long term growth potential, stock shows signs of basing and accumulation, still - it's a relatively concentrated biotech, so highly risky.

Leaderboard

Find the members with the highest scoring picks in AMRN.

Score Leader

TrackWedbush

TrackWedbush (84.83) Score: +381.18

The Score Leader is the player with the highest score across all their picks in AMRN.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
AWWWWW < 20 12/31/2014 Outperform 1Y $0.95 +262.16% +23.44% +238.72 0 Comment
Playa14 < 20 12/26/2014 Outperform 5Y $0.99 +246.46% +23.33% +223.13 0 Comment
efarev 99.02 2/3/2015 Outperform 5Y $1.03 +233.01% +25.98% +207.03 0 Comment
BENIVZ14 < 20 12/15/2014 Outperform 5Y $1.09 +214.68% +27.20% +187.48 0 Comment
rantomac 70.98 2/10/2015 Outperform 5Y $1.12 +206.25% +24.79% +181.46 0 Comment
bwlink100 46.09 4/13/2007 Underperform 1Y $29.60 -88.41% +87.47% +175.88 0 Comment
smoaky < 20 3/28/2007 Underperform 5Y $21.80 -84.27% +91.58% +175.84 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. Lolly131313 87.74 4/19/2007 Underperform 3Y $37.50 -90.85% +84.70% +175.55 0 Comment
zeccoscott < 20 4/20/2007 Underperform 3W $39.20 -91.25% +83.24% +174.49 0 Comment
littlejoyusone 74.31 4/20/2007 Underperform 3W $39.20 -91.25% +83.24% +174.49 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackJimCramer 84.94 1/3/2013 Underperform 3W $8.38 -59.07% +76.29% +135.36 0 Comment
TrackPoisedTo < 20 12/20/2012 Outperform 5Y $8.42 -59.26% +77.94% -137.20 0 Comment
TrackCitigroup 93.29 4/30/2012 Outperform NS $12.50 -88.32% +35.24% -123.56 5/12/2014 @ $1.46 0 Comment
TrackJimCramer 84.94 3/22/2012 Outperform 3W $11.91 -29.64% +4.69% -34.33 1/3/2013 @ $8.38 0 Comment
TrackMKMPartners 84.63 7/12/2011 Outperform NS $14.24 -84.34% +39.55% -123.89 1/16/2014 @ $2.23 0 Comment
TrackCanaccord 46.45 4/18/2011 Outperform NS $16.51 -87.95% +32.92% -120.87 10/18/2013 @ $1.99 0 Comment
TrackWedbush 84.83 7/20/2010 Outperform NS $2.23 +418.39% +37.21% +381.18 10/3/2012 @ $11.56 0 Comment

Featured Broker Partners